BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15388349)

  • 1. Synthesis of disaccharides derived from heparin and evaluation of effects on endothelial cell growth and on binding of heparin to FGF-2.
    O'Brien A; Lynch C; O'Boyle KM; Murphy PV
    Carbohydr Res; 2004 Oct; 339(14):2343-54. PubMed ID: 15388349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of a glucuronic acid and glucose conjugate library and evaluation of effects on endothelial cell growth.
    Pitt N; Duane RM; O'Brien A; Bradley H; Wilson SJ; O'Boyle KM; Murphy PV
    Carbohydr Res; 2004 Aug; 339(11):1873-87. PubMed ID: 15261580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts.
    Delehedde M; Lyon M; Gallagher JT; Rudland PS; Fernig DG
    Biochem J; 2002 Aug; 366(Pt 1):235-44. PubMed ID: 12000311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation.
    Foxall C; Wei Z; Schaefer ME; Casabonne M; Fugedi P; Peto C; Castellot JJ; Brandley BK
    J Cell Physiol; 1996 Sep; 168(3):657-67. PubMed ID: 8816920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-dependent fibroblast growth factor activities: effects of defined heparin oligosaccharides.
    Zhou FY; Kan M; Owens RT; McKeehan WL; Thompson JA; Linhardt RJ; Höök M
    Eur J Cell Biol; 1997 May; 73(1):71-80. PubMed ID: 9174673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cysteine-free fibroblast growth factor 1 mutant induces heparin-independent proliferation of endothelial cells and smooth muscle cells.
    Xue L; Shireman PK; Hampton B; Burgess WH; Greisler HP
    J Surg Res; 2000 Aug; 92(2):255-60. PubMed ID: 10896831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides.
    Liu L; Bytheway I; Karoli T; Fairweather JK; Cochran S; Li C; Ferro V
    Bioorg Med Chem Lett; 2008 Jan; 18(1):344-9. PubMed ID: 17981035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of a heparan sulfate mimetic disaccharide with a conformationally locked residue from a common intermediate.
    Fairweather JK; Karoli T; Liu L; Bytheway I; Ferro V
    Carbohydr Res; 2009 Nov; 344(17):2394-8. PubMed ID: 19819428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
    J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1.
    Berry D; Shriver Z; Natke B; Kwan CP; Venkataraman G; Sasisekharan R
    Biochem J; 2003 Jul; 373(Pt 1):241-9. PubMed ID: 12659634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.
    Narita K; Staub J; Chien J; Meyer K; Bauer M; Friedl A; Ramakrishnan S; Shridhar V
    Cancer Res; 2006 Jun; 66(12):6025-32. PubMed ID: 16778174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.
    Miao HQ; Ornitz DM; Aingorn E; Ben-Sasson SA; Vlodavsky I
    J Clin Invest; 1997 Apr; 99(7):1565-75. PubMed ID: 9120000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel inhibitors of fibroblast growth factor (FGF-2) binding to heparin and endothelial cell survival from a structurally diverse carbohybrid library.
    Murphy PV; Pitt N; O'Brien A; Enright PM; Dunne A; Wilson SJ; Duane RM; O'Boyle KM
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3287-90. PubMed ID: 12392734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration.
    Li D; Zhang C; Song F; Lubenec I; Tian Y; Song QH
    Microvasc Res; 2009 Mar; 77(2):134-42. PubMed ID: 18948122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cells express two isoforms of fibroblast growth factor receptor 1 with different affinities for fibroblast growth factor-2.
    Roghani M; Moscatelli D
    Prostate; 2007 Feb; 67(2):115-24. PubMed ID: 17143873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans.
    Reis RC; Schuppan D; Barreto AC; Bauer M; Bork JP; Hassler G; Coelho-Sampaio T
    Biochem Biophys Res Commun; 2005 Aug; 333(3):976-83. PubMed ID: 15985216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of FGF-2 binding to chondrocytes from the developing growth plate by perlecan.
    Govindraj P; West L; Smith S; Hassell JR
    Matrix Biol; 2006 May; 25(4):232-9. PubMed ID: 16481152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial and fibroblast cell-derived heparan sulphate bind with differing affinity to basic fibroblast growth factor.
    Pye DA; Kumar S
    Biochem Biophys Res Commun; 1998 Jul; 248(3):889-95. PubMed ID: 9704022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
    Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
    Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.